RNAZ · Transcode Therapeutics, Inc. · Executive Compensation
$1.66
-0.04 (-2.35%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to the Company's recurring and expected continuing losses from operations, the Company has concluded there is substantial doubt concerning its ability to continue as a going concern for one year after the issuance of these consolidated financial statements without additional capital becoming available.”View the 10-Q filed Aug 14, 2026
Market Cap
$28.78M
Shares
16.93M
Volume · Oct 20
20.17K
Avg daily vol (3M)
53.41K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Thomas A. Fitzgerald | Vice President, Chief Financial Officer, and former interim Chief Executive Officer | $1,069,615 |
| Philippe P. Calais | Chief Executive Officer | $373,808 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Thomas A. Fitzgerald | Interim Chief Executive Officer, Vice President and Chief Financial Officer | $956,966 |
| Robert Michael Dudley | Former Chief Executive Officer | $85,432 |
| Philippe P. Calais | Chief Executive Officer | — |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Robert Michael Dudley | Former Chief Executive Officer | $642,766 |
| Thomas A. Fitzgerald | Interim Chief Executive Officer, Vice President and Chief Financial Officer | $426,862 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Robert Michael Dudley | Former Chief Executive Officer | $805,027 |
| Thomas A. Fitzgerald | Interim Chief Executive Officer, Vice President and Chief Financial Officer | $560,701 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Robert Michael Dudley | Chief Executive Officer | $495,484 |
| Thomas A. Fitzgerald | Vice President and Chief Financial Officer | $317,613 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Robert Michael Dudley | Chief Executive Officer | $42,978 |
| Thomas A. Fitzgerald | Vice President and Chief Financial Officer | $15,386 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| John Tattory | Interim Chief Financial Officer | Appointed | 2026-09-11 |
| Thomas A. Fitzgerald, M.B.A. | member of the Board of Directors | Resigned | 2026-09-11 |
| Thomas A. Fitzgerald, M.B.A. | Chief Financial Officer | Resigned | 2026-09-11 |
| Magda Marquet | member of the Audit Committee of the Board | Resigned | 2025-12-22 |
| Jack Stover | Director | Appointed | 2025-12-22 |
| Philippe Calais | Chief Executive Officer | Appointed | 2025-10-08 |
| Tom Fitzgerald | Interim Chief Executive Officer | Resigned | 2025-10-08 |
| Elizabeth Czerepak | independent board member | Appointed | 2025-10-08 |
| Philippe Calais | Chief Executive Officer | Appointed | 2025-10-08 |
| Philippe Calais | Chief Executive Officer | Appointed | 2025-10-08 |
| Thomas Fitzgerald | Interim Chief Executive Officer | Resigned | 2025-10-08 |
| Philippe Calais | chairperson of the Company's Audit Committee and as a member of the Company's Compensation Committee | Resigned | 2025-10-08 |
| Elizabeth Czerepak | member and chairperson of the Audit Committee | Appointed | 2025-10-08 |
| Elizabeth Czerepak | Board | Appointed | 2025-10-08 |
| Thomas A. Fitzgerald | Interim President and Chief Executive Officer | Appointed | 2024-01-16 |
| Robert Michael Dudley | director | Resigned | 2024-01-16 |
| Robert Michael Dudley | President and Chief Executive Officer | Resigned | 2024-01-16 |
Leadership
- Philippe Calais CEO
- Philippe P. Calais CEO, Board Member
- Thomas A. Fitzgerald CEO, CFO
- John Tattory CFO
- Zdravka Medarova CTO
- Elizabeth Czerepak Board Member
- Erik Manting Board Member
- Jack E. Stover Board Member
- Jack Stover Board Member
- Magda Marquet Board Member